BREAKING 🚨: The #FDA has approved capivasertib in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer [previously metastatic hormone-sensitive prostate cancer (mHSPC)], as detected by an FDA-authorized test. urologytimes.com/view/fda-ap…

BREAKING 🚨: The #FDA has approved belzutifan in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as adjuvant treatment for patients with ccRCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. @DrChoueiri @DanaFarberNews urologytimes.com/view/fda-ap…

🚨 PRIMARY2: PSMA-PET moves into the prostate cancer diagnostic pathway 📰Just out in @TheLancetOncol 🧬 660 biopsy-naïve pts w/ suspected significant PCa PI-RADS 3 MRI or PI-RADS 2 MRI w/ high-risk clinical features ⚖️Randomized to [⁶⁸Ga]Ga-PSMA-11 PET-CT vs systematic transperineal biopsy. 🧭 PRIMARY score 1–2 → surveillance. PRIMARY score 3–5 → PSMA-targeted biopsy. 🎯 PSMA-PET triage was non-inferior for clinically significant PCa detection: 12% vs 16% ✂️ Nearly half avoided biopsy: 49% (163/331). 📉 Clinically insignificant cancer detection dropped substantially: 14% vs 32%. ⚖️ Big implication: fewer biopsies less overdiagnosis, without losing significant cancers. 💡Caveat: follow-up ongoing; health economics validation w/ other PSMA tracers needed 🔗shorturl.at/RWxr7 @PCFnews @PCF_Science @renalandurology @UrologyTimes @urotoday

In this episode of The UroOnc Minute, host Adam Weiner, MD, (@Adam_Weiner535) sits down with Carissa Chu, MD, (@CChuMD) to discuss the evolving understanding of variant histology in bladder cancer and its implications for clinical practice. #AUA26 @UCSFUrology urologytimes.com/view/the-ur…

WATCH: Kevin Zorn, MD, FRCSC, FACS, (@Dr_KevinZorn) discusses the factors that clinicians should consider when selecting among different MIST options for BPH. #AUA26 urologytimes.com/view/kevin-…

WATCH: Jonathan D. Harper, MD, (@uroharper) discusses findings from a secondary analysis of the PUSH trial showing that modest increases in urine volume and lower urine osmolality were associated with reduced kidney stone recurrence. #AUA26 @uwurology urologytimes.com/view/jonath…

In a recent episode of The UroOnc Minute, host Adam Weiner, MD, (@Adam_Weiner535) spoke with Chad Tang, MD, (@ChadTangMD) about the impact of imaging modality on the benefit of metastasis-directed therapy for oligometastatic prostate cancer. Catch the full episode here: urologytimes.com/view/the-ur…

The @US_FDA has approved RadioMedix's generic Ga-68 PSMA-11, a PSMA-targeted diagnostic radiopharmaceutical for PET imaging in patients with prostate cancer. urologytimes.com/view/fda-ap…

Drs. @flavell_rob & @anilbidkar1 sat down with @UrologyTimes to discuss preclinical findings showing that combining CD46-directed alpha radiation with ADC therapy produced superior antitumor activity in prostate cancer models over either treatment alone. urologytimes.com/view/precli…

Results from the phase 1 AcTION trial showed a manageable safety profile up to 10 MBq with 225Ac-PSMA-617 in men with mCRPC. #ASCO26 @drlouiseemmett urologytimes.com/view/phase-…

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, (@AmyPearlman1) sits down with Annah Vollstedt, MD, to discuss the evolving landscape of female pelvic medicine, including implantable tibial nerve stimulation, the role of pelvic floor physical therapy, and the future of incontinence care. @UIowa_urology Watch the full episode here: urologytimes.com/view/pearls…

WATCH: Nicole Miller, MD, FACS, discusses her approach to evaluating and managing patients who experience persistent or recurrent lower urinary tract symptoms after treatment for BPH. @VUMCurology #AUA26 urologytimes.com/view/nicole…

Results from the pivotal phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer have been published in The Lancet Oncology. #pcsm @OHSUurology urologytimes.com/view/publis…

🚨 STAMPEDE: AI biomarker may help select who needs abi intensification in VHR localized #prostatecancer Just out in @Annals_Oncology 🧬 >1k pts w/ non-metastatic very high-risk PCa from 2 randomized STAMPEDE phase 3 abi trials. 🤖 Multimodal AI using routine H&E PSA/stage/age 📉 MMAI very high-risk: abi LT-ADT markedly improved MFS: HR 0.47. 5-yr MFS 81% vs 62%. 🎯 MMAI standard high-risk: benefit was limited: HR 0.83. 5-yr MFS 84% vs 82%. Interaction P=0.02. 🧠 Signal in both node-negative & node-positive pts ⚖️ Implication: intensify where benefit is ⬆️, spare overtreatment/toxicity where benefit is ⬇️. 🔗shorturl.at/FoHKo @PCFnews @PCF_Science @urotoday @UrologyTimes

🚨Metastasis-directed therapy for #ProstateCancer🚨 🎙️ This week @ChadTangMD discusses oligometastatic disease on the #UroOncMinute @MDAndersonNews @UrologyTimes 🔗 shorturl.at/vYDl3

Experts discuss how the treatment paradigm for MIBC is rapidly evolving with the emergence of effective perioperative strategies for cisplatin-ineligible patients. @MaxKates @UrogerliMD @abhinav__khanna urologytimes.com/view/periop…